by Raynovich Rod | Nov 25, 2015 | Biopharmaceuticals
Slow But Steady Biotech Rally RNA Therapeutics-Duchenne Muscular Dystrophy (DMD) Despite some overhanging concerns about drug pricing and major setbacks from clinical trials like Clovis Oncology (CLVS) and BioMarin Pharmaceutical (BMRN) the sector looks like it wants...
by Raynovich Rod | Nov 19, 2015 | 2023-24 Life Science Portfolios, 2024 Rayno Biopharmaceuticals Portfolio, 2024 Rayno Tools and Diagnostics Portfolio
Update-1 Rayno Recap for week of 11/20/15 IBB up 3.04%, XBI up 1.92%, XLV up 2.82% Notable Small Cap Winners Curis (CRIS) up 4.13%, Fibrocell Sciences (FCSC) up 3.42%, Geron (GERN) up 4.82%, Ignyta (RXDX) up 37.39%, and Ocera Therapeutics (OCRX) up 5.31%. Notable...
by Raynovich Rod | Nov 13, 2015 | Biopharmaceuticals, Clinical Diagnostics and Tools
Update 11/16 PM Biotech Rally Underperforms Energy up 2.99% and Telecom up 1.81% The S&P and Dow rallied past Paris attack and terrorism concerns after an early morning stall. Biotechs underperformed weighed down by the Clovis Oncology (CLVS) NDA delay. The IBB...
by Raynovich Rod | Nov 9, 2015 | Biopharmaceuticals
Small Caps Hot, Large Caps Not Curis (CRIS) and Fibrocell Science (FCSC) Lead the Way Up Biotech stocks could not extend last month’s rally in choppy trading that left major indices up but off mid-week highs. The healthcare sector sold off on continued pricing...
by Raynovich Rod | Oct 30, 2015 | Biopharmaceuticals
Biotech Innovation Seeks Value Healthcare Costs Mount The Bio Investor Forum has become a go-to meeting for biotech investors and company executives. Although the presenting companies are early stage or smaller cap public companies the attendees are broadly...
by Raynovich Rod | Oct 27, 2015 | Biopharmaceuticals
10/29/15 Update Large Cap Biotechs Update Amgen (AMGN) Revenues Grow 14%, beats street. 2016 Revenues guided to ~$22B, flattish revenue growth with higher EPS $10.35-$10.75. 2015 PEG=1.80, P/S=5.94, Div. 1.94% Rayno Biopharmaceutical Portfolio Large Caps up 2.6% YTD,...
by Raynovich Rod | Oct 27, 2015 | Biopharmaceuticals
Update-1… 11/9 Small Caps Outperform CRIS $2.62, GERN $3.92, OCRX $3.41 Bio Investor Forum-A Runway for Emerging Biotech Companies These are risky times for small cap biotech investments as you know the group took a big hit in July/August and are extremely...
by Raynovich Rod | Oct 23, 2015 | Biopharmaceuticals
General Issues from Bio Investor Forum See BIOtechNow for detailed articles on BIF#15 Biotech executives and investors came with a record 900 attendees to this annual event which presents key issues in the industry and offers a networking forum with 175 presenting...
by Raynovich Rod | Oct 22, 2015 | Biopharmaceuticals
Summary for the Week of Oct 19:Markets Up on Central Banks Easing;Techs Lead the Way IBB up 0.62%- 316.3 bottomed on Wednesday. QQQ up 4.3%- 112.78 up big Thursday and Friday. XBI down o.58%- 65.67 in choppy trading. XLI up 4%- 54.66 steady climb from Monday. XLV...
by Raynovich Rod | Oct 19, 2015 | Biopharmaceuticals
October 21 Update 9:45a EDT NASDAQ up 0.4% IBB up 1.57% 1:45p EDT Biotech Thrashing Continues-High Fliers Hit Hardest Healthcare stocks remain under attack with the XLV down 1.5% and the IBB down 1.6%.Healthcare is the sector loser down 2% while the Industrials are...